Sofosbuvir induced leucocytoclasic vasculitis: a case report.

Q2 Medicine BMC Dermatology Pub Date : 2019-05-17 DOI:10.1186/s12895-019-0086-4

Elena Campione, Annunziata Dattola, Monia Di Prete, Daniele Di Paolo, Amedeo Ferlosio, Augusto Orlandi, Luca Bianchi

{"title":"Sofosbuvir induced leucocytoclasic vasculitis: a case report.","authors":"Elena Campione, Annunziata Dattola, Monia Di Prete, Daniele Di Paolo, Amedeo Ferlosio, Augusto Orlandi, Luca Bianchi","doi":"10.1186/s12895-019-0086-4","DOIUrl":null,"url":null,"abstract":"Background: We describe a case of leucocytoclasic vasculitis induced by Sofosbuvir and its disappearence after the end of the therapy. The hepatitis C virus, firstly described in 1989, is a major global health problem, with high morbidity and mortality. We observed a temporal relationship between the treatment and the onset of vasculitis. We emphasize the multidisciplinary approach to the patients with liver disease to improve the quality of life of these patients.Case presentation: A 53-year-old Caucasian man with a history of hepatitis C virus genotype 1 infection was examined at our Department of Dermatology for the occurrence of palpable purpura. The patient referred that the first appearance of the dermatoses was about one month after initiation of therapy with Sofosbuvir for hepatitis C.Conclusions: Vasculitis appeared after the beginning of Sofosbuvir and, even though it was treated with different medications proved to be effective, it disappeared only after the conclusion of the therapy, giving a strong evidence to be a drug eruption.","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"19 1","pages":"6"},"PeriodicalIF":0.0000,"publicationDate":"2019-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-019-0086-4","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12895-019-0086-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Background: We describe a case of leucocytoclasic vasculitis induced by Sofosbuvir and its disappearence after the end of the therapy. The hepatitis C virus, firstly described in 1989, is a major global health problem, with high morbidity and mortality. We observed a temporal relationship between the treatment and the onset of vasculitis. We emphasize the multidisciplinary approach to the patients with liver disease to improve the quality of life of these patients.

Case presentation: A 53-year-old Caucasian man with a history of hepatitis C virus genotype 1 infection was examined at our Department of Dermatology for the occurrence of palpable purpura. The patient referred that the first appearance of the dermatoses was about one month after initiation of therapy with Sofosbuvir for hepatitis C.

Conclusions: Vasculitis appeared after the beginning of Sofosbuvir and, even though it was treated with different medications proved to be effective, it disappeared only after the conclusion of the therapy, giving a strong evidence to be a drug eruption.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

索非布韦致白细胞破裂性血管炎1例。

背景:我们描述了一例由索非布韦引起的白细胞破坏性血管炎，并在治疗结束后消失。丙型肝炎病毒于1989年首次被描述，是一个主要的全球卫生问题，发病率和死亡率都很高。我们观察到治疗与血管炎发病之间的时间关系。我们强调肝病患者的多学科方法，以提高这些患者的生活质量。病例介绍:一名53岁的白人男性，有丙型肝炎病毒基因型感染史，在我皮肤科检查可触及的紫癜的发生。患者提到，该皮肤病首次出现是在索非布韦治疗丙型肝炎开始一个月后。结论:索非布韦开始治疗后出现血管炎，尽管用不同的药物治疗均有效，但在治疗结束后才消失，有力地证明是药疹。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMC Dermatology Medicine-Dermatology

自引率

0.00%

发文量

期刊介绍： BMC Dermatology is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of skin disorders, as well as related molecular genetics, pathophysiology, and epidemiology. BMC Dermatology (ISSN 1471-5945) is indexed/tracked/covered by PubMed, MEDLINE, CAS, EMBASE, Scopus and Google Scholar.